Business
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET.\n\nIn order to participate in the audio webcast, interested parties can register and access the live webcast under \"News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.\n\nABOUT AURINIA\n\nAurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of LN. The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20201112006061/en/\n\nInvestor & Corporate Contact:\nGlenn Schulman, PharmD, MPH\nSVP, Corporate Communications & IR\[email protected]\n\nSource: Aurinia Pharmaceuticals Inc.","length":2671,"tagName":"div"}]